ES2178633T3 - Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos. - Google Patents

Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.

Info

Publication number
ES2178633T3
ES2178633T3 ES91910904T ES91910904T ES2178633T3 ES 2178633 T3 ES2178633 T3 ES 2178633T3 ES 91910904 T ES91910904 T ES 91910904T ES 91910904 T ES91910904 T ES 91910904T ES 2178633 T3 ES2178633 T3 ES 2178633T3
Authority
ES
Spain
Prior art keywords
growth factor
beta
insulin
concomitating
fci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910904T
Other languages
English (en)
Inventor
Harry N Antoniodes
Samuel E Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Molecular Biology Inc
Harvard University
Original Assignee
Institute of Molecular Biology Inc
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Molecular Biology Inc, Harvard University filed Critical Institute of Molecular Biology Inc
Application granted granted Critical
Publication of ES2178633T3 publication Critical patent/ES2178633T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA CURACION DE UNA HERIDA EXTERNA Y/O REGENERACION OSEA DE UN MAMIFERO ADMINISTRANDOLE UNA COMPOSICION QUE CONTIENE FACTOR BETA DEL CRECIMIENTO PURIFICADO DE TRANSFORMACION Y FACTOR-I DEL CRECIMIENTO PURIFICADO PARECIDO A LA INSULINA O FACTOR-II DEL CRECIMIENTO PURIFICADO PARECIDO A LA INSULINA.
ES91910904T 1990-05-30 1991-05-30 Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos. Expired - Lifetime ES2178633T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53064990A 1990-05-30 1990-05-30

Publications (1)

Publication Number Publication Date
ES2178633T3 true ES2178633T3 (es) 2003-01-01

Family

ID=24114431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910904T Expired - Lifetime ES2178633T3 (es) 1990-05-30 1991-05-30 Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.

Country Status (7)

Country Link
EP (1) EP0531425B1 (es)
JP (1) JP3377524B2 (es)
AT (1) ATE222117T1 (es)
CA (1) CA2082420C (es)
DE (1) DE69133087T2 (es)
ES (1) ES2178633T3 (es)
WO (1) WO1991018622A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288628A (en) * 1992-06-24 1994-02-22 The Procter & Gamble Company Rat osteosarcoma cell line OSR4TR1
US5264358A (en) * 1992-06-24 1993-11-23 The Procter & Gamble Company Rat osteosarcoma cell line OSR9TR1
US5286644A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line OSR-2
US5286645A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line osr3tr1
US5292656A (en) * 1992-06-24 1994-03-08 The Procter & Gamble Company Rat osteosarcoma cell line OSR-6
US5286643A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line OSR-8
KR100385293B1 (ko) * 2000-05-13 2003-05-23 주식회사 리젠 바이오텍 βｉｇ-ｈ3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
JP2014156410A (ja) * 2013-02-14 2014-08-28 Nagoya Univ 組織形成用組成物及びその利用
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS61291521A (ja) * 1983-06-03 1986-12-22 アメリカ合衆国 ヒト血小板もしくはヒト胎盤由来の精製β型トランスホ−ミング成長因子
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
ATE84065T1 (de) * 1986-10-09 1993-01-15 Fujisawa Pharmaceutical Co Expressionsvektor fuer menschlichen insulinaehnlichen wachstumsfaktor-i.
NZ222413A (en) * 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
DE3785758T2 (de) * 1986-11-14 1993-08-05 Harvard College Wundheilung und knochenregeneration.
AU1340688A (en) * 1987-01-30 1988-08-24 Techne Corporation Transforming growth factor-beta
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
EP0323842A3 (en) * 1988-01-07 1990-04-25 Otsuka Pharmaceutical Co., Ltd. Method of purification of transforming growth factor-beta
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
CA1341598C (en) * 1988-07-15 2009-09-29 Central Sydney Area Health Service Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound

Also Published As

Publication number Publication date
EP0531425A1 (en) 1993-03-17
EP0531425A4 (en) 1997-08-27
WO1991018622A1 (en) 1991-12-12
DE69133087D1 (de) 2002-09-19
EP0531425B1 (en) 2002-08-14
CA2082420A1 (en) 1991-12-01
JP3377524B2 (ja) 2003-02-17
CA2082420C (en) 2004-07-20
JPH05507488A (ja) 1993-10-28
DE69133087T2 (de) 2003-04-03
ATE222117T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
SI0633259T1 (en) Sulfonylaminopyrimidines, their preparation and their use as medicine
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
MX9201869A (es) Proceso para la estabilizacion fotoquimica y termica de material de fibra de poliamida y composicion que contiene diarilamida del acido oxalico utilizada en el proceso.
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
IT8709354A0 (it) Siringa per iniezioni,in specie endovenose,realizzata per poteressere usata una sola volta,senza possibilita' di riaspirazione.
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
GEP20002300B (en) Purified Forms of Dnase, Method for Its Production, Pharmaceutical Composition and Use Thereof
NO2004009I1 (no) Melagatran, stereoisomerer derav eller fysiologisksalter eller estrer derav
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
BR9100843A (pt) Inalador e embalagem de medicamento para aplicacao com o mesmo
IT1256450B (it) Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione
AR009244A1 (es) Forma cristalina de la 4-[5-metil-3-fenilisoxazol-4-il]bencensulfonamida, composicion para uso farmaceutico, uso de dicha composicion en la fabricacionde un medicamento y metodo para preparar los cristales
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
KR930012022A (ko) 뇌조직 보호용 모다피닐(Modafinil)
DE69116184D1 (de) Topisch anwendbare Zusammensetzungen auf der Basis von hoch molekularer Hyaluronsäure zur Behandlung von Entzündungen der Mundhöhle, zu deren Hygiene und kosmetischer Behandlung
ES2089199T3 (es) Composicion curable.
ATE84029T1 (de) Substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antimikrobieller wirksamkeit.
ES2181165T3 (es) Uso de un peptido asociado a la latencia para la preparacion de un medicamento para aumentar la curacion de heridas.
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ITMI921223A1 (it) Composizioni poliestere/isocianato reticolabili adatte alla preparazione di manufatti in composito particolarmente con processi ad iniezione, procedimento per la loro preparazione e loro utilizzo
CA2082420A1 (en) Wound healing composition comprising purified igf-i or igf-ii and a purified tgf-.beta.
ES2108122T3 (es) Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
ES2049697T3 (es) Producto para el tratamiento del cabello y el cuerpo.
ES2086526T3 (es) Aplicacion medicinal de m-csf.